Trk Receptors

TRK-IN-24 is a potent inhibitor of Trk receptors, specifically targeting TRKA, TRKC, TRKAG595R, TRKAG667C, and TRKAF589L, with IC50 values of 5.21, 4.51, 6.77, 1.42, and 6.13 nM, respectively. This compound demonstrates significant antitumor activity in xenograft models, including BaF3-CD74-NTRK1G595R and BaF3-CD74-NTRK1G667C. Additionally, TRK-IN-24 effectively inhibits the proliferation of Ba/F3 cells harboring various single mutants, achieving IC50 values ranging from 1.43 to 47.56 nM. This makes TRK-IN-24 a valuable tool for research applications focused on targeted cancer therapies.

Trk-IN-7 is a potent TRK inhibitor targeting TRKA, TRKB, and TRKC, with IC50 values ranging from 0.25 to 10 nM. Additionally, Trk-IN-7 demonstrates significant inhibitory activity against EML4-ALK and various ALK mutations, including G1202R, C1156Y, R1275Q, F1174L, L1197M, and G1269A, with IC50 values ranging from 5 to 50 nM. This compound is valuable for research in neurotrophic signaling and cancer biology, particularly involving TRK and ALK pathways.

Trk-IN-8 is a potent TRK inhibitor that exhibits IC50 values of 0.42 nM for TRKAa, 0.89 nM for TRKA(G595R), and 1.5 nM for TRKC(G623R). This compound is effective in selectively targeting Tropomyosin receptor kinase (TRK) signaling pathways, making it a valuable tool for research in cancer biology and therapeutic development. Its high selectivity and potency facilitate studies of TRK-related oncogenic processes and potential treatment strategies for TRK fusion-positive tumors.

Trk-IN-20 is a potent inhibitor of Trk kinases, specifically targeting TrkA, TrkB, and TrkC with IC50 values of 1.6 nM, 2.9 nM, and 2.0 nM, respectively. By inhibiting the phosphorylation of these receptors, Trk-IN-20 effectively suppresses their kinase functions. This compound is valuable in research applications aimed at understanding neurotrophic signaling pathways and exploring therapeutic strategies for conditions related to Trk receptor dysregulation.

GZ-389988 is a potent pan-TRK inhibitor that targets TRKA, TRKB, and TRKC with IC50 values of 0.3 nM, 0.1 nM, and 0.5 nM, respectively. It is valuable for the study of NTRK fusion-positive tumors, facilitating research into their biological mechanisms and potential therapeutic strategies. This compound supports the investigation of TRK-related pathways and their role in oncogenesis.

RET/TRKA-IN-1 is a dual inhibitor targeting both RET and TRKA, with an IC50 value of 0.375 µM for RET. This reagent has demonstrated significant anti-proliferative effects on LC-2 and KM12 cell lines, exhibiting GI50 values of 0.72 µM and 0.25 µM, respectively. Additionally, RET/TRKA-IN-1 effectively induces cell cycle arrest at the G1 phase, making it a valuable tool for research on cancer biology and therapeutic development.

TIY-7 is a selective and orally active inhibitor of tropomyosin receptor kinases (TRKs). It demonstrates potent enzyme inhibition with IC50 values of 2.9 nM for TRKA and as low as 0.2 nM for TRKCG696A, showcasing its efficacy against various TRK mutations. TIY-7 exhibits significant anti-tumor activity in mouse xenograft models, making it a valuable tool for research in cancer biology and targeted therapy development.

hTrkA-IN-2 is a selective allosteric inhibitor of human TrkA with an IC50 of 3.9 nM. This compound demonstrates the ability to modulate TrkA activity, making it valuable for studies investigating neurotrophic signaling pathways. hTrkA-IN-2 is suitable for research applications focused on neurobiology, potential therapeutic strategies for neurodegenerative diseases, and the exploration of pain mechanisms.

TRK-IN-28 is a potent TRK inhibitor that demonstrates IC50 values of 0.55 nM, 25.1 nM, and 5.4 nM against TRKWT, TRKG595R, and TRKG667C, respectively. This compound exhibits antiproliferative activity, with IC50 values of 9.5 nM, 3.7 nM, 205.0 nM, and 48.3 nM in various Ba/F3 cell lines expressing ETV6-TRKAWT, ETV6-TRKBWT, LMNA-TRKG595R, and LMNA-TRKAG667C, respectively. TRK-IN-28 is valuable for research focused on TRK-related tumors and signaling pathways.

Trk-IN-11 is a highly effective inhibitor of tropomyosin receptor kinase (TRK), exhibiting IC50 values of 1.4 nM and 1.8 nM against TrkA and TrkAG595R, respectively. As a receptor tyrosine kinase, TRK plays a crucial role in the progression of solid tumors. This compound is valuable for studying TRK-related pathways and assessing therapeutic strategies in cancer research.

(R)-Larotrectinib is a selective TRK inhibitor, demonstrating an IC50 value of 28.5 nM for TrkA. This compound is instrumental in advancing research on cancers associated with TRK fusions, offering potential insights into therapeutic strategies. Additionally, (R)-Larotrectinib may contribute to the understanding of inflammatory and certain infectious diseases, making it a valuable reagent for diverse biomedical investigations.

Pan-Trk-IN-2 is a small molecule inhibitor targeting the Trk receptor family. It demonstrates potent antitumor activity by interfering with nerve growth factor signaling pathways. This compound is useful for research applications focused on cancer biology and the therapeutic exploration of neurotrophic receptor pathways.

Trk-IN-1 is a potent inhibitor of tropomyosin-related kinases (Trk), demonstrating significant activity against TrkA with an IC50 of 3.7 nM and TrkB with an IC50 of 94 nM. This compound is useful for studying the role of Trk signaling in various biological processes, including neuronal growth and survival. Trk-IN-1 can be applied in drug discovery efforts aimed at treating conditions associated with Trk dysregulation, such as certain neurodegenerative diseases and cancers.

TrkA-IN-7 is a selective inhibitor of Tropomyosin Receptor Kinase A (TrkA), exhibiting a Kd value of 40 μM. This compound serves as a valuable tool for investigating the role of TrkA in various biological processes, including neurotrophic signaling and cancer progression. Its application in research facilitates the exploration of therapeutic strategies targeting TrkA-related pathways.

Trk-IN-10 is a selective inhibitor of tropomyosin receptor kinases (TRK) with IC50 values of 0.86 nM for TrkA and 6.92 nM for the TrkAG595R variant. As a receptor tyrosine kinase, TRK plays a crucial role in the development of solid tumors. Trk-IN-10 exhibits a noteworthy selectivity profile, showing an IC50 of 350 nM against ALK, which may help mitigate potential off-target effects and toxicity in therapeutic applications. This compound is valuable for research into TRK-related pathways and the treatment of neurotrophic receptor-driven malignancies.

Trk-IN-6 is a selective inhibitor of Trk receptors, demonstrating remarkable in vitro potency against various TRK mutants with IC50 values ranging from 0.2 to 0.7 nM. This compound is invaluable for studying the role of Trk signaling in cancer and neurodevelopmental disorders. Its high specificity makes it a reliable tool for elucidating the biological effects of Trk inhibition in research applications.

TRK-IN-34 is a potent TRK and TRKC mutant kinase inhibitor, exhibiting IC50 values of 0.75 nM and 0.96 nM against TRKAG595R and TRKAG667C, respectively. This compound effectively inhibits the kinase activities of these mutations, leading to decreased proliferation of TRKA-transfected cells and demonstrating tumor growth-inhibitory effects in xenograft models. TRK-IN-34 is valuable for investigating cancers resistant to TRK inhibitors, particularly those driven by the TRKAG667C mutation.

TrkC-IN-1 is a selective inhibitor of Tropomyosin receptor kinase C (TrkC), exhibiting IC50 values of 3.3-7.1 μM in EBC-1 cells and 7.3-10.2 μM in HT-29 cells. This compound demonstrates significant potential in cancer research, particularly in elucidating the role of TrkC in oncogenic signaling pathways. TrkC-IN-1 is a valuable tool for studying the therapeutic implications of targeting TrkC in various cancer types.

Type II TRK inhibitor 1 is a selective inhibitor targeting TRK fusion proteins and wild-type TRK, demonstrating potent anti-proliferative effects in Ba/F3 cell lines that express the CD74-TRKAG667C and ETV6-TRKCG696C variants, with IC50 values of 6 nM and 1.7 nM, respectively. Additionally, this compound functions as a click chemistry reagent, featuring an alkyne group that facilitates copper-catalyzed azide-alkyne cycloaddition (CuAAc), enabling its application in bioconjugation and related chemical biology research.

D5261 is a potent allosteric inhibitor of tropomyosin-related kinase A (TrkA). It selectively targets the type III binding site, effectively modulating TrkA activity. D5261 has shown promise in biological assays for studying neuronal development and neurodegenerative diseases, making it a valuable tool for research focused on neurobiology and related therapeutic applications.

Anizatrectinib is a highly potent and orally bioavailable TrkA kinase inhibitor with an IC50 value of 1.3 nM. This compound plays an important role in the investigation of inflammatory diseases, including prostatitis and other pelvic conditions. Its mechanism of action offers valuable insights into cellular signaling pathways associated with pain and inflammation, making it a useful tool for researchers in the field of therapeutic development.

NMS-P626 is a potent inhibitor of the tropomyosin receptor kinase A (TRKA), TRKB, and TRKC, demonstrating IC50 values of 8 nM, 7 nM, and 3 nM, respectively. This compound effectively inhibits the proliferation of KM12 colorectal cancer cells by suppressing the phosphorylation of TPM3-TRKA and disrupting downstream signaling pathways, with an observed IC50 of 19 nM in these cells. NMS-P626 is valuable for research applications focused on colorectal cancer and related signaling mechanisms.

(3aR)-Selitrectinib is a potent TRK kinase inhibitor, demonstrating IC50 values of 0.6 nM for TRKA and less than 2.5 nM for TRKC. This next-generation compound is designed to target TRK signaling pathways, making it a valuable tool in cancer research. Its selective inhibition of TRK kinases can aid in the investigation of tumorigenesis and the therapeutic potential in TRK fusion-positive cancers.

ONO-7579 is an orally bioavailable inhibitor targeting TRKA, primarily inhibiting its phosphorylation to reduce tumor growth. In studies with colorectal cancer cell line KM12, it exhibits an EC50 of 17.6 ng/g, indicating that this concentration effectively reduces phosphorylated TRKA activity by 50%. ONO-7579 is useful in cancer research, particularly in exploring therapeutic strategies against tumors reliant on TRKA signaling.

TrkA-IN-8 is a potent TrkA inhibitor with a Kd value of 3.3 µM. This compound demonstrates concentration-dependent inhibition of cell proliferation in lung cancer cell lines, particularly in non-small cell lung cancer. TrkA-IN-8 is valuable for research applications aimed at understanding the role of TrkA signaling in oncogenesis and therapeutic resistance.

VMD-928 is an orally active, allosteric, and irreversible inhibitor targeting tropomyosin receptor kinase A (TrkA). By blocking the downstream signaling pathways initiated by nerve growth factor (NGF) binding, VMD-928 inhibits cell proliferation and invasion while promoting cancer cell apoptosis. This compound is of significant interest in research related to various cancers, including prostate cancer, thymic carcinoma, mesothelioma, squamous cell carcinoma of the head and neck, lung squamous cell carcinoma, ovarian cancer, and hepatocellular carcinoma.

Zurletrectinib is a potent tyrosine kinase inhibitor that selectively targets TRK kinases (TRKA IC50 = 0.81 nM; TRKB IC50 = 0.145 nM; TRKC IC50 = 0.184 nM). Its enhanced binding affinity results in superior efficacy, especially against various resistance mutations (effectively targeting 13 out of 18 known mutations). This compound is particularly useful for research applications related to glioma and exploring TRK signaling pathways in tumor biology.

Tepotinib hydrochloride is a highly selective, reversible, ATP-competitive inhibitor of c-Met, exhibiting an IC50 of 3 nM and over 200-fold selectivity for c-Met compared to other kinases such as IRAK4, TrkA, Axl, IRAK1, and Mer. This compound effectively inhibits c-Met phosphorylation and promotes autophagy. Tepotinib hydrochloride demonstrates significant antitumor activity and is applicable in cancer research targeting c-Met-driven pathways.

Entrectinib-d8 is a deuterated derivative of Entrectinib, targeting TrkA/B/C, ROS1, and ALK receptors. This compound exhibits potent inhibitory effects with IC50 values of 1 nM for TrkA, 3 nM for TrkB, 5 nM for TrkC, and 12 nM for ROS1 and ALK. Entrectinib-d8 is effective in inducing apoptosis and cell cycle arrest in various cancer cell lines, demonstrating significant anti-tumor activity. Additionally, it has been shown to alleviate bleomycin-induced pulmonary fibrosis in murine models, making it a valuable tool for research in cancer and fibrosis therapies.

PF-07245303 is an ITK/TRK inhibitor that effectively reduces the production of pro-inflammatory cytokines such as IL-4 and IFNγ. This compound inhibits the phosphorylation of PLCγ1 and disrupts nerve growth factor-induced basophil activation and TRKA phosphorylation. Additionally, PF-07245303 demonstrates a reduction in oxazolone-induced ear swelling in mouse models, making it a valuable tool for research into atopic dermatitis and related inflammatory conditions.